Angiotensin Receptor–Neprilysin Inhibition

@article{Havakuk2017AngiotensinRI,
  title={Angiotensin Receptor–Neprilysin Inhibition},
  author={Ofer Havakuk and Uri Elkayam},
  journal={Journal of Cardiovascular Pharmacology and Therapeutics},
  year={2017},
  volume={22},
  pages={356 - 364}
}
  • O. HavakukU. Elkayam
  • Published 1 July 2017
  • Biology
  • Journal of Cardiovascular Pharmacology and Therapeutics
The novel combination sacubitril/valsartan represents a new therapeutic approach in the management of heart failure. With the simultaneous blockage of the enzyme neprilysin (by sacubitril) and angiotensin II receptors (by valsartan), this combination reduces the degradation of natriuretic peptides and other counterregulatory peptide systems while avoiding the deleterious effect of angiotensin II receptors activation and thereby encompasses a beneficial impact of 2 important neurohormonal… 

Figures and Tables from this paper

Effect of angiotensin receptor neprilysin inhibitors on left atrial remodeling and prognosis in heart failure

The effects of ARNI and ACEI/ARB on left atrial (LA) remodelling in heart failure with reduced ejection fraction (HFrEF) is compared.

Recent major advances in cardiovascular pharmacotherapy

The aim of this review is to summarize the recent major advances in cardiovascular pharmacotherapy, with a focus on the new approved drug for treatment of heart failure with reduced ejection fraction; proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors; and the novel reversal agents for non-vitamin K oral anticoagulants (NOACs).

Brain Natriuretic Peptide and Its Biochemical, Analytical, and Clinical Issues in Heart Failure: A Narrative Review

It is essential to design assays that can recognize specific forms of BNP, NT-proBNP, and proBNP to obtain more clinical information and to enhance their diagnostic, therapeutic, and prognostic values.

Sacubitril/Valsartan as a Therapeutic Tool Across the Range of Heart Failure Phenotypes and Ejection Fraction Spectrum

The role of S/V is reconsidered in the light of different HF phenotypes and on the basis of HF considered as a whole spectrum, representing a fundamental therapeutic strategy, although with different magnitudes depending on the severity and the stage of the clinical syndrome.

TRIF/EGFR signalling mediates angiotensin-II-induced cardiac remodelling in mice

It is supported that cardiac TRIF was a potential therapeutic target for attenuating cardiac pathophysiological remodelling and partially explained the molecular mechanism of Ang-II/aldosterone-induced cardiac inflammation, fibrosis, hypertrophy and dysfunction in mice.

The Persistent Mortality and Heart Failure Burden of Anterior ST-Segment Elevation Myocardial Infarction Following Primary Percutaneous Coronary Intervention

Despite prior improvements in STEMI outcomes in the reperfusion era related to the broad adoption of timely PCI, there is a persistent high mortality and CHF burden in patients with anterior STEMI.

Assessment of acute heart failure prognosis: the promising role of prognostic models and biomarkers

A precise methodological approach should be set for the derivation and validation of prognostic models in AHF with unified characteristics to establish an effective performance in clinical practice.

Brain-Heart Communication

574 Vascular complications of transcatheter aortic valve replacement : A concise literature review

  • 2017

References

SHOWING 1-10 OF 55 REFERENCES

Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction

The dual‐acting angiotensin receptor neprilysin inhibitor LCZ696 improves clinical outcome patients with heart failure with reduced ejection fraction, and pilot data suggest potential benefit in heart Failure with preserved ejections fraction (HFpEF).

Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics.

The current knowledge of the use and effects of NEPinh alone or in combination with other therapeutic agents for the treatment of human cardiovascular disease such as HF and hypertension is summarized.

Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients.

LCZ696 was superior to enalapril in reducing both sudden cardiac deaths and deaths from worsening heart failure, which accounted for the majority of cardiovascular deaths.

Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure.

The NEP and ACE inhibitory activities of BMS-182657 act synergistically and mimic the interaction resulting from combining selective inhibitors of these enzymes, and has acute hemodynamic effects in hamsters with heart failure greater than those produced by selective inhibition of NEP or ACE.

Angiotensin-neprilysin inhibition versus enalapril in heart failure.

LCZ696 was superior to enalapril in reducing the risks of death and of hospitalization for heart failure and decreased the symptoms and physical limitations of heart failure.

Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy.

The superior renoprotection achieved by AVE7688 over enalapril in progressive renal injury is due to the correction of the altered balance of vasoconstrictor/vasodilator mediators in the kidney.

Concomitant Angiotensin AT1 Receptor Antagonism and Neprilysin Inhibition Produces Omapatrilat-like Antihypertensive Effects Without Promoting Tracheal Plasma Extravasation in the Rat

Dual inhibition of angiotensin-converting enzyme (ACE) and neprilysin (NEP) by drugs such as omapatrilat produces superior antihypertensive efficacy but cause high incidence of angioedema. We

Valsartan/Sacubitril for Heart Failure: Reconciling Disparities Between Preclinical and Clinical Investigations.

Recent translational science studies involving the central nervous system and the eye suggest that other effects of valsartan/sacubitril might influence its use in some patients.

Neutral endopeptidase 24.11 inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failure

Despite significant activation of the ANP system, reflected by a dose-dependent increase in plasma cyclic GMP concentrations, high doses of candoxatril induced systemic vasoconstrictory rather than vasocilatory effects in patients with CHF, therefore NEP inhibition by candox atril may not exhibit beneficial haemodynamic effects in CHF.

EFFECTS OF UK 69 578: A NOVEL ATRIOPEPTIDASE INHIBITOR

...